SCHEMBL5825759

SCHEMBL5825759

O=C(Oc1ccccc1Oc1ccnc2ccccc12)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.48
▸ METAP2 P50579 1/20 0.48
▸ METAP1 P53582 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ MAPT P10636 4/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ ESR1 P03372 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ SRC P12931 3/20 0.47
▸ TGFBR1 P36897 3/20 0.47
▸ PARP1 P09874 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17199398 0.90 MAPT (0.54) LMNAMETAP2METAP1HDAC6KMT2A
SCHEMBL38661023 0.79 ESR1 (0.56) LMNAKMT2AMAPTSMN1; SMN2MEN1
SCHEMBL27159853 0.78 LMNA (0.47) LMNAMETAP2METAP1HDAC6MAPT
SCHEMBL7482565 0.78 SRC (0.53) KMT2AMAPTSMN1; SMN2HSD17B10MEN1
SCHEMBL9431770 0.78 NCF1 (0.54) MAPTSMN1; SMN2HSD17B10ALOX15ALDH1A1
SCHEMBL38660920 0.76 KMT2A (0.60) KMT2AMAPTSMN1; SMN2HSD17B10MEN1
SCHEMBL2309532 0.76 CYP1A2 (0.45) LMNASMN1; SMN2ALOX15BRAFKDR
SCHEMBL725404 0.74 KMT2A (0.76) LMNAMETAP2METAP1HDAC6KMT2A
SCHEMBL4472632 0.74 KDM4E (0.43) LMNAKMT2AMAPTSMN1; SMN2MEN1
SCHEMBL27665935 0.74 PDGFRB (0.49) LMNAKMT2AMAPTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 — — US disclosed
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-21 — — US disclosed
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-07-08 — — US disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA LMNA 1836/4885METAP2 4606/4885METAP1 4267/4885
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA LMNA 2078/4885METAP2 4534/4885METAP1 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback